Taiyo Holdings Co., Ltd. · TSE:4626
Taiyo — Q3 FY2018 Earnings Presentation
17 slides from Taiyo's earnings presentation, Feb 2, 2018
Slide 1: Consolidated Financial Result Digest FY2018 Q3
Consolidated Financial Result Digest FY2018 Q3 (Fiscal Year Ending March 31, 2018) Z TAIYO HOLDINGS CO., LTD. February 2, 2018 Any information incorporated in this document is not intended for suggestion of purchase or sale of equity share of the company. All the description and projection are based
Slide 2: Terminology
1 Terminology Term Definition PWB Printed wiring boards SR “Solder resist ink” or “Solder mask” PKG Semiconductor packages
Slide 3: Classification of Product
2 Classification of Product Group Category Type Remarks high-end Rigid Liquid regular ・SR materials for insulation and surface PWB protection use PKG Liquid/Dry Film insulating materials FPC Liquid/Dry Film ・build-up materials for interlayer insulation and Build-up Liquid/Dry Film hole plugging use
Slide 4: FY2018 Q3 Overview
3 FY2018 Q3 Overview 1 Yen depreciating against the U.S. dollar more than the expected exchange rate *Actual exchange rate: 1USD=112yen / Expected exchange rate (as of Oct. 31): 1USD=108yen 2 Sales volume decreased year-on-year in regular rigid, meanwhile, increased in both DF (Dry Film) and FPC 3 R
Slide 5: FY2018 Q3 Consolidated Financial Results
4 FY2018 Q3 Consolidated Financial Results Results summary JPY millions FY2018 FY2017 FY2018 full year progress Q3 Q3 new YoY % rate results results forecasts Net sales 35,922 39,022 +3,100 +9% 51,300 76% Operating 7,188 8,699 +1,511 +21% 10,800 81% income Ordinary 7,302 8,659 +1,357 +19% 10,700 81%
Slide 6: FY2018 Q3 Net Sales (YoY)
5 FY2018 Q3 Net Sales (YoY) Analysis of Net Sales JPY millions +2,672 -126 +554 Foreign currency Decrease in Increase in fluctuation, sales volume sales volume change in product of PWB etc. of DF mix, etc. 35,922 39,022 FY2017 Q3 FY2018 Q3
Slide 7: FY2018 Q3 Operating Income (YoY)
6 FY2018 Q3 Operating Income (YoY) Analysis of Operating Income JPY millions +1,272 -65 +304 Foreign currency Increase in fluctuation, Decrease in sales volume change in product sales volume of DF mix, etc. of PWB etc. 7,188 8,699 FY2017 Q3 FY2018 Q3
Slide 8: FY2018 Q3 Sales Results by Product Group Category
7 FY2018 Q3 Sales Results by Product Group Category Sales Results by Product Group Category JPY millions FY2016 Q3 FY2017 Q3 20,000 FY2018 Q3 16,318 15,496 15,172 15,000 11,626 9,858 9,937 10,000 8,021 7,187 7,163 5,000 2,692 2,371 2,695 2,052 1,298 1,356 0 Rigid (high-end) Rigid (regular) PKG Build
Slide 9: FY2018 Q3 Segment Information
8 FY2018 Q3 Segment Information Sales by Segment (including inter-segment sales or transactions) JPY millions 20,000 FY2017 Q3 FY2018 Q3 15,000 10,000 15,361 16,610 13,239 14,887 5,000 7,677 7,059 6,453 7,629 3,033 3,141 0 Japan China Taiwan Korea Other Operating Income by Segment (including inter-s
Slide 10: Trend of Quarterly Performance
9 Trend of Quarterly Performance Net Sales & Operating Income JPY millions Net sales（left axis） ● Operating income (right axis） 16,000 4,000 14,000 3,500 3,000 12,000 2,500 10,000 2,000 8,000 1,500 6,000 1,000 4,000 500 2,000 0 0 (500) Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4
Slide 11: Revision to FY2018 Consolidated Earning Forecasts
10 Revision to FY2018 Consolidated Earning Forecasts Forecasts Revision Summary JPY millions FY2018 FY2018 FY2018 full year full year Q3 previous new Change Change results forecasts(A) forecasts(B) (B-A) (%) Net sales 39,022 50,000 51,300 1,300 3% Operating 8,699 10,200 10,800 600 6% income Ordinary
Slide 12: Medical and Pharmaceutical Business
Medical and Pharmaceutical Business
Slide 13: Company Profile
® Company Profile DOoneRI(C KLOBSA OxR7 PIL Company Name AE vy vVvtAstt / TAIYO Pharma Co., Ltd. Established August 2, 2017 Capital 450 million yen Representative Eiji Sato Director Chairman of the Board and Representative Masao Arima President and Representative Director Business Area Development,
Slide 14: New Business (Beginning to explore the medical and pharmaceutical manufacturing businesses)
13 New Business (Beginning to explore the medical and pharmaceutical manufacturing businesses)
Slide 15: Considering Entry
Means of Entry @Assume long listed drugs @Corporate acquisition @Plant acquisition @Own plant Copyright © TAIYO HOLDINGS CO., LTD. All Rights Reserved. Growth Strategy Proprietary products + No drug development + Improve profitability of long listed drugs + Assume additional long listed drugs - Auth
Slide 16: Right Transfer of Long-Term Listed Products
15 Right Transfer of 13 Long-Term Listed Products
Slide 17: TAIYO HOLDINGS CO., LTD.
TAIYO HOLDINGS CO., LTD. Copyright YO HOLDINGS CO., LTD. All Rights Reserved.